Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Dara- Revlimid, Ixazomib & Dex: A Promising Option for Some Myeloma Patients| Andrew Yee, MD #IMS25
HealthTreeDescription
Discover the latest research presented at #IMS2025 with Dr. Andrew Yee as he discusses a new treatment option for patients with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. This study explores the use of daratumumab (Dara) combined with Revlimid, ixazomib, and dexamethasone, and what it could mean for improving outcomes and quality of life.
If you or a loved one has myeloma, learn how this combination therapy may offer new hope and what experts are saying about its potential role in frontline treatment.
🔔 Subscribe to our channel for more updates from IMS 2025 and the latest in myeloma research.
#MultipleMyeloma #MyelomaTreatment #MyelomaResearch #IMS2025
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.